Patent application number | Description | Published |
20100260726 | Methods for Producing a Non Human Model for Aortic Aneurysm - The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof. | 10-14-2010 |
20110275791 | A B Cell Depleting Agent for the Treatment of Atherosclerosis - The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis. | 11-10-2011 |
20120076754 | Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis - The present invention relates to the prevention or treatment of atherosclerosis, using an IL-17 polypeptide and pharmaceutical compositions thereof. | 03-29-2012 |
20120225427 | sPLA2 IIA Polymorphism Analysis for the Diagnosis/Prognosis of a Cardiovascular Disease/Event - The invention relates to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising determining, in a sample obtained from said subject, the presence or absence of a variant allele of nucleotide polymorphism (SNP) of the sPLA2 type IIA nucleic acid, wherein the SNP is selected from the group consisting of rs11573156 and rs2236771, wherein the presence of the minor allele (G) of SNP rs11573156 indicates an increased risk of having or being at risk of having or developing a cardiovascular disease and/or cardiovascular event, and the presence of the minor allele (C) of SNP rs2236771 indicates a decreased risk of having or being at risk of having or developing a cardiovascular disease and/or cardiovascular event. | 09-06-2012 |
20120311728 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS - The present invention relates to the prevention or treatment of atherosclerosis, in particular to a group X sPLA2 polypeptide for use in the treatment of atherosclerosis. | 12-06-2012 |
20130017557 | COMBINATION OF sPLA2 TYPE IIA MASS AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENTAANM Mallat; ZiadAACI ParisAACO FRAAGP Mallat; Ziad Paris FRAANM Tedgui; AlainAACI ParisAACO FRAAGP Tedgui; Alain Paris FRAANM Tsimikas; SotiriosAACI La JollaAAST CAAACO USAAGP Tsimikas; Sotirios La Jolla CA USAANM Witztum; JosephAACI La JollaAAST CAAACO USAAGP Witztum; Joseph La Jolla CA US - The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event. | 01-17-2013 |
20130224215 | A B Cell Depleting Agent for the Treatment of Atherosclerosis - The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis. | 08-29-2013 |
20140004540 | METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR EVENT IN A SUBJECT | 01-02-2014 |
20150050290 | Method and Pharmaceutical Composition for use in the Treatment or the Prevention of Aneurysm - The present invention relates to a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression for use in the treatment or the prevention of aneurysm. In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression. | 02-19-2015 |